Latest Breaking News On - கை ய்வ் எக்கர்டத் - Page 1 : comparemela.com
Search jobs 05-May-2021 Evotec and the GCKD study enter into strategic collaboration to build a unique molecular patient database
BIOSPECIMENS FROM >5,000 CKD (CHRONIC KIDNEY DISEASE) PATIENTS FROM THE GCKD COHORT STUDY WILL BE SCREENED AND ANALYSED USING EVOTEC’S EVOPANOMICS AND EVOPANHUNTER PLATFORMS
THE GENERATION OF LONGITUDINAL DATA FOR THOUSANDS OF CKD PATIENTS WILL RESULT IN AN UNPRECEDENTED MOLECULAR PATIENT DATABASE
THE STRATEGIC COLLABORATION PROVIDES UNIQUE OPPORTUNITIES TO DEEPEN THE UNDERSTANDING OF DISEASE MECHANISMS, PROGRESSION AND POTENTIAL COMPLICATIONS
Hamburg and Erlangen, Germany, 04 May 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the University Hospital Erlangen today announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease (“GCKD”) cohort study. Under the agreement, the research team will make use of Evotec’s
Germany
Erlangen
Bayern
Hamburg
Berlin
German
Kai-uwe-eckardt
Mario-schiffer
Head-of-the-institute-genetic-epidemiology
Steering-committee
University-of-freiburg
University-hospital-erlangen
Evotec AG: Evotec and the GCKD Study Enter into Strategic Collaboration to Build A Unique Molecular Patient Database
PANOMICS AND EVO
PANHUNTER PLATFORMS
THE GENERATION OF LONGITUDINAL DATA FOR THOUSANDS OF CKD PATIENTS WILL RESULT IN AN UNPRECEDENTED MOLECULAR PATIENT DATABASE
THE STRATEGIC COLLABORATION PROVIDES UNIQUE OPPORTUNITIES TO DEEPEN THE UNDERSTANDING OF DISEASE MECHANISMS, PROGRESSION AND POTENTIAL COMPLICATIONS
HAMBURG and ERLANGEN, GERMANY / ACCESSWIRE / May 4, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the University Hospital Erlangen today announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease ( GCKD ) cohort study. Under the agreement, the research team will make use of Evotec s proprietary
Germany
Erlangen
Bayern
Hamburg
Berlin
German
Volker-braun
Kai-uwe-eckardt
Mario-schiffer
Gabriele-hansen
Evopanomics-evopanhunter
Steering-committee
New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
Program Evaluated the Safety and Efficacy of Vadadustat in Adult Patients with Anemia Due to CKD on Dialysis and Not on Dialysis
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the
2VATE) and adult patients not on dialysis (PRO
2TECT) in two separate manuscripts.
Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is Akebia s lead product candidate. In late March 2021, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat for the treatment of anemia due to CKD in both adult patients on dialysis
Germany
Japan
Cambridge
Cambridgeshire
United-kingdom
Berlin
Massachusetts
United-states
Glenn-chertow
Kai-uwe-eckardt
Stevenk-burke
Kristenk-sheppard
vimarsana © 2020. All Rights Reserved.